This paper is in the following e-collection/theme issue:

Pilot studies (ehealth) (103)

Published on in Vol 6 , No 7 (2022) :July

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/34248, first published .
The Burden of Cold Agglutinin Disease on Patients’ Daily Life: Web-Based Cross-sectional Survey of 50 American Patients

The Burden of Cold Agglutinin Disease on Patients’ Daily Life: Web-Based Cross-sectional Survey of 50 American Patients

The Burden of Cold Agglutinin Disease on Patients’ Daily Life: Web-Based Cross-sectional Survey of 50 American Patients

Authors of this article:

Florence Joly 1 Author Orcid Image ;   Lisa Anne Schmitt 2 Author Orcid Image ;   Patricia Ann McGee Watson 3 Author Orcid Image ;   Emilie Pain 4 Author Orcid Image ;   Damien Testa 5 Author Orcid Image
Article Authors Cited by (1) Tweetations (2) Metrics

Journals

  1. Röth A, Broome C, Barcellini W, Jilma B, Hill Q, Cella D, Tvedt T, Yamaguchi M, Lee M, Shafer F, Wardęcki M, Jiang X, Patel P, Joly F, Weitz I. Sutimlimab provides clinically meaningful improvements in patient‐reported outcomes in patients with cold agglutinin disease: Results from the randomised, placebo‐controlled, Phase 3 CADENZA study. European Journal of Haematology 2023;110(3):280 View